Agilent's Dako Lands FDA Approval for Lung Cancer Complementary Dx | GenomeWeb

NEW YORK (GenomeWeb) – Agilent Technologies today announced its subsidiary Dako has received US Food and Drug Administration approval for a complementary diagnostic for Bristol-Myers Squibb's non-squamous non-small cell lung cancer (NSCLC) drug Opdivo (nivolumab).

The complementary diagnostic, PD-L1 IHC 28-8 pharmDx, identifies PD-L1 expression levels on the surface of NSCLC cells and provides information on the survival benefit of treatment with Opdivo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.